

<rss version="2.0"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:wfw="http://wellformedweb.org/CommentAPI/"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:slash="http://purl.org/rss/1.0/modules/slash/">

    <channel>
        <title>PharmiWeb.com Articles</title>
        <atom:link href="https://www.pharmiweb.com/rss/articles" rel="self" type="application/rss+xml" />
        <link>https://www.pharmiweb.com</link>
        <description>PharmiWeb.com | Articles in the Pharmaceutical industry</description>
        <lastBuildDate>Mon, 01 Jun 2026 12:15:58 +00:00</lastBuildDate>
        <language>en-GB</language>
        <sy:updatePeriod>hourly</sy:updatePeriod>
        <sy:updateFrequency>1</sy:updateFrequency>
                <item>
                    <title>Top 10 Clinical Trial Solution Providers in 2026 for Sponsors, CROs, Biotech, and MedTech</title>
                    <link>https://www.pharmiweb.com/article/top-10-clinical-trial-solution-providers-in-2026-for-sponsors-cros-biotech-and-medtech</link>
                    <pubDate>Tue, 26 May 2026 09:11:04 +00:00</pubDate>
                    <guid isPermaLink="false">234006</guid>
                    <description><![CDATA[

This guide compares the top clinical trial solution providers in 2026, including enterprise leaders like Oracle Health Sciences, Medidata, and Veeva Systems, alongside rapidly growing AI-focused platforms such as Clinion and specialized vendors like Clario and Signant Health.
Clinical trials are no longer powered by standalone Electronic Data Capture (EDC) systems alone. In 2026, sponsors and CROs are looking for unified eClinical ecosystems that combine EDC, RTSM, CTMS, eTMF, eConsent, and...]]></description>
                </item>
                <item>
                    <title>The Importance of Scalable Software Systems for Healthcare and Insurance Providers</title>
                    <link>https://www.pharmiweb.com/article/the-importance-of-scalable-software-systems-for-healthcare-and-insurance-providers</link>
                    <pubDate>Wed, 20 May 2026 05:35:30 +00:00</pubDate>
                    <guid isPermaLink="false">233745</guid>
                    <description><![CDATA[Healthcare and insurance organisations manage large volumes of data, customer interactions, and operational processes every day. As these industries continue to evolve, the pressure to deliver faster services, maintain compliance, and improve user experiences has increased significantly. Businesses that rely on outdated systems often struggle to keep up with changing demands and operational complexity.
This is why scalable software systems have become increasingly important. A scalable platfo...]]></description>
                </item>
                <item>
                    <title>21 CFR Part 11 Compliance in Clinical Trials: Complete Guide to Electronic Records &amp; Signatures</title>
                    <link>https://www.pharmiweb.com/article/21-cfr-part-11-compliance-in-clinical-trials-complete-guide-to-electronic-records-signatures</link>
                    <pubDate>Wed, 27 May 2026 10:55:46 +00:00</pubDate>
                    <guid isPermaLink="false">234090</guid>
                    <description><![CDATA[

21 CFR Part 11 compliance defines how electronic records and electronic signatures can be used in FDA-regulated clinical trials and research environments. The regulation outlines requirements for system validation, audit trails, access controls, electronic signatures, and data integrity to help ensure electronic records remain accurate and traceable throughout the clinical trial lifecycle.



Overview of 21 CFR Part 11 Compliance in Clinical Trials

Clinical trials generate large volumes of...]]></description>
                </item>
                <item>
                    <title>The often-overlooked shortcomings of standard toxicology tests </title>
                    <link>https://www.pharmiweb.com/article/the-often-overlooked-shortcomings-of-standard-toxicology-tests</link>
                    <pubDate>Wed, 20 May 2026 08:38:58 +00:00</pubDate>
                    <guid isPermaLink="false">233762</guid>
                    <description><![CDATA[For decades, toxicology has relied on a relatively small set of laboratory tests to understand how chemicals cause toxicity. These techniques typically show the ‘what’, but not necessarily the ‘how’, i.e., the tests show what toxicity damage could arise, but not how or why. However, this mechanistic understanding is vital for understanding the toxicological properties of chemicals.
 
High Content Screening (HCS) may hold the key to solving these problems and improving toxicology testing, espe...]]></description>
                </item>
                <item>
                    <title>HCPs Are Already Using AI. Is Your Commercial Model up to speed?</title>
                    <link>https://www.pharmiweb.com/article/hcps-are-already-using-ai-is-your-commercial-model-up-to-speed</link>
                    <pubDate>Tue, 12 May 2026 12:07:05 +00:00</pubDate>
                    <guid isPermaLink="false">233160</guid>
                    <description><![CDATA[A doctor finishes a consultation and turns back to their screen. An AI tool summarises the latest literature, compares treatment options and highlights the most relevant guideline recommendations. The doctor reviews the summary, considers the patient context and makes a decision.
Later that day a pharmaceutical representative arrives to discuss the same therapy, inevitably, his words or slides compete with excerpts and recommendations from multiple AI sources the doctor has already reviewed....]]></description>
                </item>
                <item>
                    <title>Exploring the Pharma and Biotech Investment Landscape in Oxygen-Based Therapies</title>
                    <link>https://www.pharmiweb.com/article/exploring-the-pharma-and-biotech-investment-landscape-in-oxygen-based-therapies</link>
                    <pubDate>Tue, 12 May 2026 11:58:01 +00:00</pubDate>
                    <guid isPermaLink="false">233148</guid>
                    <description><![CDATA[Oxygen-based therapies have long been part of standard medical care, but they’re now drawing fresh interest from investors and innovators alike. As healthcare systems adapt to rising chronic disease rates and the growing demand for home-based treatment, oxygen-based therapies are moving into a more commercial space. Pharma companies, biotech firms and medical device manufacturers are increasingly exploring opportunities tied to respiratory care, portable delivery systems and newer application...]]></description>
                </item>
                <item>
                    <title>Why Pharma and Biotech Facilities Are Rethinking How They Manage Clinical Operations</title>
                    <link>https://www.pharmiweb.com/article/why-pharma-and-biotech-facilities-are-rethinking-how-they-manage-clinical-operations</link>
                    <pubDate>Mon, 04 May 2026 06:13:48 +00:00</pubDate>
                    <guid isPermaLink="false">232640</guid>
                    <description><![CDATA[Running a pharmaceutical or biotech facility is one of the most operationally complex undertakings in modern medicine. You are managing clinical research workflows, drug inventory pipelines, patient trial data, regulatory documentation, and multidisciplinary teams — all at the same time, all with zero tolerance for error. For years, many of these operations ran on a combination of manual processes, standalone software tools, and institutional memory held by a handful of senior staff.
That app...]]></description>
                </item>
                <item>
                    <title>The Hidden Operational Implications of MFN Drug Pricing</title>
                    <link>https://www.pharmiweb.com/article/the-hidden-operational-implications-of-mfn-drug-pricing</link>
                    <pubDate>Wed, 06 May 2026 04:40:36 +00:00</pubDate>
                    <guid isPermaLink="false">232868</guid>
                    <description><![CDATA[The Most Favored Nation (MFN) drug pricing policy is gaining momentum in the United States. While the policy’s breadth of implementation is still unclear, pharmaceutical manufacturers must be ready for the full range of potential market disruptions.
All 17 pharmaceutical manufacturers named by the Trump administration have made individual deals to offer some prescriptions at MFN prices. However, the exact terms of each agreement are confidential, making it difficult to understand the agreemen...]]></description>
                </item>
    </channel>
</rss>